Video using JMP Clinical 19 was posted in December 2025. 

 Do you run clinical trials or work at a sponsoring or regulatory agency supporting clinical trials? Is patient safety related to new or improved medications critical to your organization’s success? Do you need to understand the possible benefit-risk profiles of novel therapies?  Are you challenged to identify events or medications that tend to occur simultaneously, or the overlap of medications being used while patients are experiencing Adverse Events (AEs)?

Because AEs occur spontaneously and over time, designing the most appropriate analysis in advance is challenging and nearly impossible. Their temporal relationships to treatment, concomitant medications, or death provide additional challenges to understanding patient safety.

JMP Clinical 19 includes new features to further our understanding of the benefit-risk profiles of novel therapies. In this Developer Tutorial, JMP Principal Research Fellow, Richard Zink, demonstrates three key new reports that consider the timing of adverse events as it informs our understanding patient safety.  He shows how to use and interpret:

• Recurrence - Understand the safety of events that occur repeatedly within patients over time.
• Co-occurrence– Examine all observed pairs of AEs and medications to describe the extent of their overlap in time.
• Nearby Occurrences - Select reference occurrences of interest (AEs, concomitant medications, or death) and find nearby occurrences that appear within time windows defined around the start or stop dates of the reference occurrences. Alternatively, identify nearby occurrences as those events that have any overlap in time with the reference occurrences.

Resources

• JMP Clinical Software Documentation and Updates
• Main page for CDISC study referenced in this demo
• Sample data used in the demo
• Summary of what is new in JMP Clinical 19 by Geoffrey Mann
• An overview of features in JMP® Clinical to analyze adverse events by Richard Zink
• Recurrence reports. Recurrence: An analysis of adverse events whose time has come in clinical trials blog
• Co-occurrent reports. Assessing the duration of overlap of medications and adverse events blog
• Nearby occurrences. Understanding temporal relationships of patient experiences and their importance to patient safety blog
• Visualizing co-occurrence using the JMP Network Plot add-in by Richard Zink
• Getting Started with JMP Clinical short videos

Sample data:

• CDISC Pilot. A 3-arm multicenter randomized double-blind study of 2 doses of Xanomeline transdermal patch versus placebo in patients with mild-to-moderate Alzheimer’s disease.
• Nicardipine. A 2-arm multicenter randomized double-blind study of high-dose intravenous nicardipine versus placebo in patients with subarachnoid hemorrhage. Shipped with JMP Clinical.
• Theophylline. A  simulated 2-arm multicenter randomized study of two doses of theophylline (300 and 400 mg) that can be used to demo the Pharmacokinetics report. (Only ADSL and PC are available.)  Shipped with JMP Clinical.

Other new capabilities related to clinical trials:

• Dynamic Survival : Provides a more interactive experience for summarizing time-to-event endpoints using output from the JMP Survival and Proportional Hazard platforms allowing for visualizing changes in accumulating information or timing of interim analyses.. A more dynamic survival analysis experience blog.
• Subgroup Screening: Leverages Response Screening platform to summarize how the treatment effect (or the treatment response, in the case of single arm studies) varies within subgroups and what factors might contribute to this heterogeneity. For a deep dive, click here. Introducing the Subgroup role in the Response Screening and Fit Model platforms of JMP Pro 19 blog.